# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN-TD
- Date: 1983-09-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for new patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT. **S**

## Objective

Hemoglobin: 13.8 g/dL; White cell count: 7.9 10*3/uL; Platelets: 290 10*3/uL; Sodium: 138 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.9 mg/dL; eGFR: 92 mL/min/1.73 m²; Calcium: 9.6 mg/dL; Albumin: 4 g/dL; ALT: 24 U/L; AST: 22 U/L; Alkaline phosphatase: 98 U/L; Total bilirubin: 0.6 mg/dL; Glucose: 96 mg/dL; PHQ-9: 5. All results are synthetic.

BP 132/80 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 96% on room air; weight 72.4 kg; BMI 22.9 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window; Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis; Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoring. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallel. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracture. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care team. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
